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Vascular Endothelial Growth Factor Secretion
by Nonmyocytes Modulates Connexin-43 Levels
in Cardiac Organoids
Rohin K. Iyer, Ph.D.,1 Devang Odedra, M.A.Sc,2 Loraine L.Y. Chiu, M.A.Sc,2
Gordana Vunjak-Novakovic, Ph.D.,3 and Milica Radisic, Ph.D.1,2,4
We previously showed that the sequential, but not simultaneous, culture of endothelial cells (ECs), fibroblasts
(FBs), and cardiomyocytes (CMs) resulted in elongated, beating cardiac organoids. We hypothesized that the
expression of Cx43 and contractile function are mediated by vascular endothelial growth factor (VEGF) released
by nonmyocytes during the preculture period. Cardiac organoids (*200 mm diameter) were cultivated in mi-
crochannels to enable rapid screening. Three experimental groups were formed: (i) Simultaneous Preculture
(ECs + FBs for 48 h, followed by CMs), (ii) Sequential Preculture (ECs for 24 h, FBs for 24 h, followed by CMs),
and (iii) Simultaneous Triculture (ECs +FBs +CMs). Controls included CMs only, FBs only, and ECs only
groups, and preculture with ECs only or FBs only. The highest VEGF levels were found in the Preculture groups
[Simultaneous Preculture, 8.9 – 2.7 ng/(mL$h- 1); Sequential Preculture, 16.6 – 3.4 ng/(mL$h - 1)], as compared
with Simultaneous Triculture where VEGF was not detectable, as shown by enzyme-linked immunosorbent
assay. Analytical flow cytometry showed that VEGFR2 was expressed by ECs (86% – 2 VEGFR2+ ), FBs (44% – 1
VEGFR2 + ), and CMs (49% – 2 VEGFR2 + ), showing that all three cell types were capable of responding to
changes in VEGF. Addition of anti-VEGF neutralizing IgG (0.4 mg/mL) to Simultaneous Preculture resulted in
3-fold decrease in Cx43 mRNA and 1.5-fold decrease in Cx43 protein, while Simultaneous Triculture supple-
mented with VEGF ligand (30 ng/mL) had a threefold increase in Cx43 mRNA and a twofold increase in Cx43
protein. Addition of a small molecule inhibitor of the VEGFR2 receptor (19.4 nM) to Sequential Preculture caused
a 1.4-fold decrease in Cx43 mRNA and a 4.1-fold decrease in Cx43 protein. Cx43 was localized within CMs, and
not within FBs or ECs. Enriched CM organoids and Sequential Preculture organoids grown in the presence
of VEGFR2 inhibitor displayed low levels of Cx43 and poor functional properties. Taken together, these re-
sults suggest that endogenous VEGF-VEGFR2 signaling enhanced Cx43 expression and cardiac function in
engineered cardiac organoids.
Introduction
Cardiomyocytes (CMs) are responsible for generation ofcontractile force,1,2 but are only one of the three major
cell populations found in the heart. The remaining cells, or
nonmyocytes (fibroblasts [FBs] and endothelial cells [ECs]),
play important roles in matrix deposition, vascularization,
and paracrine signaling.2,3 We previously showed that pre-
culture of ECs and FBs prior to seeding CMs resulted
in beating cardiac organoids resembling myofibers.4 In
contrast, the same ratios of CMs, FBs, and ECs cultured
simultaneously (‘‘Simultaneous Triculture’’) resulted in non-
functional organoids lacking expression of the key gap
junctional marker Connexin-43 (Cx43).4 Addition of condi-
tioned medium from precultured organoids to organoids
engineered from CMs alone also improved the functional
properties and viability of the organoids,4 suggesting a role
of factors secreted by nonmyocytes on cardiac organoid
function.
Connexins are a conserved family of transmembrane
proteins that assemble into gap junctions, allowing for in-
tercellular communication and direct exchange of small
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molecules, ions, and second messengers between cells.5 Cx43
(43 kDa) is found abundantly in the heart, enabling coupling
between adjacent CMs. FBs can also couple to CMs through
Cx43 as well as Connexin-45 (Cx45) and can therefore
transmit electrophysiological gradients to contractile myo-
cytes, though they cannot exert contractile force on their
own.6,7 ECs also express Cx438 and enhance Cx43 expression
in CMs when grown in co-culture.9
Vascular endothelial growth factor (VEGF) signaling has
been implicated in the upregulation of Cx43 expression in
CMs,10 but the precise mechanism of action has not been
extensively studied. In one study, it was demonstrated that
uniaxial stretch-induced upregulation of Cx43 expression
could be blocked by anti-VEGF antibody.10 In a different
study, transgenic mice expressing only one of the three
isoforms of VEGF also showed markedly reduced Cx43 ex-
pression and impaired cardiac function and angiogenesis
compared with the wild-type mice.11
We hypothesized that VEGF-A165, an abundant isoform of
VEGF with affinity for heparin-like domains, is secreted by
FBs and ECs during preculture, resulting in upregulation of
Cx43 and improved cardiac function. To test this hypothesis,
we investigated the secretion of VEGF in different types of
monocultures and cocultures of CMs, ECs, and FBs, and the
related effects on the presence of Cx43 and functional
properties of engineered cardiac organoids. We made several
interesting observations: (i) VEGF is secreted at higher con-
centrations during preculture of nonmyocytes than during
Simultaneous Triculture of all three cell types, (ii) the source of
VEGF is the nonmyocytes, and (iii) VEGF-VEGFR2 binding
affects expression of Cx43 at both the transcriptional and
translational levels. We also observed that VEGFR2 was ex-
pressed in all three cell types (ECs, FBs, and CMs) and that
Cx43 was mostly associated with CMs. Finally, we demon-
strated, through manipulation of VEGF expression and elec-
trical field stimulation testing, the existence of a causal
relationship between VEGF-VEGFR2 signaling, Cx43mRNA/
protein expression levels, and cardiac contractile function.
Methods
Microfabrication of poly(ethylene glycol) templates
The technique for poly(ethylene glycol) microchannel
fabrication has been previously described.4 Please see Sup-
plementary Data for details.
Cells
Neonatal rat heart cells were isolated using serial colla-
genase digestions as previously described.4,12,13 Neonatal rat
cardiac FBs were obtained from the adherent cell fraction in
the neonatal rat heart isolate after 1 h of preplating. The cells
remaining in suspension after 2· 1 h preplating steps were
termed Enriched CMs. Neonatal rat microvascular ECs were
obtained from adherent cells during preplating by trypsini-
zation and magnetic activated cell sorting for cells positive
for the EC surface marker CD31. Detailed methods are
described in Supplementary Data.
Experimental design
The experimental groups investigated to identify the pos-
sible sources and targets of VEGF signaling are summarized
in Table 1. Three coculture groups were formed: (i) Si-
multaneous Preculture, as in our earlier work,4,14 where FBs
and ECs were simultaneously seeded and cultured for 2 days
prior to CM seeding; (ii) Sequential Preculture, as in our
more recent work,15 where ECs were first seeded for 24 h to
allow cord formation, followed by FBs 24 h later to stabilize
the cords, and CMs after an additional 24 h; (3) Simultaneous
Triculture,4,13 where all three cell types (ECs, FBs, and CMs)
were seeded simultaneously and cultured together. Orga-
noids consisting of ECs, or FBs or Enriched CMs served as
monoculture controls, while organoids precultured with ECs
(Preculture ECs) or FBs (Preculture FBs) served as cocul-
ture controls. Organoids were cultivated for up to 7 days
in CM/FB medium (see Supplementary Data) alone or in
medium supplemented with either VEGF ligand, or VEGF
Table 1. Cell Seeding Numbers and Percentages for Experimental Groups
Experimental group
Number of ECs (%EC)/preculture
time + cultivation time
Number of FBs (%FB)/preculture
time + cultivation time
Number of CMs
(%CM)/cultivation time
ECs only 94000 (100%)/1 + 7 days 0 0
FBs only 0 26000 (100%)/1 + 7 days 0
Enriched CMs 0 0 80000 (100%)/7 days
Preculture ECs 120000 (60%)/2 + 7 days 0 80000 (40%)/7 days
Preculture FBs 0 120000 (60%)/1 + 7 days 80000 (40%)/7 days
Simultaneous Preculture 94000 (47%)/2 + 7 days 26000 (13%)/2 + 7 days 80000 (40%)/7 days
Sequential Preculture 16000 (8%)/2 + 7 days 64000 (32%)/1 + 7 days 120000 (60%)/7 days
Simultaneous Triculture 94000 (47%)/0 + 7 days 26000 (13%)/0 + 7 days 80000 (40%)/7 days
Organoids were cultivated as monocultures (ECs only, FBs only, and Enriched CMs), coculture controls (Preculture with only ECs,
Preculture with only FBs), or as tricultures (Preculture/Tricuture). Two types of Preculture groups were used: Simultaneous Preculture,
where the nonmyocytes (ECs and FBs) were simultaneously seeded and co-cultured for 2 days prior to addition of the CMs; and Sequential
Preculture, where the ECs were seeded and cultivated for 24 h, followed by FBs for an additional 24 h, prior to CM seeding. In Simultaneous
Triculture, ECs, FBs, and CMs were all seeded at the same instant. The inclusion of monoculture and coculture controls allowed for
determination of which cell types were secreting the most endogenous VEGF by ELISA, while the inclusion of both Sequential and
Simultaneous Preculture groups was useful in determining whether conditions known to support vascular cord formation would enable even
greater VEGF secretion than Preculture without cords.
ECs, endothelial cells; FBs, fibroblasts; CMs, cardiomyocytes; VEGF, vascular endothelial growth factor; ELISA, enzyme-linked
immunosorbent assay.
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neutralizing antibody or VEGFR2 inhibitor. The culture
medium was collected 1 h prior to and 1 h following all cell
seeding steps/medium changes for enzyme-linked immu-
nosorbent assay (ELISA) analysis (Fig. 1A). Total mRNA
and protein were harvested at 1 h and 24 h, respectively,
following CM seeding. Immunofluorescence microscopy was
conducted on organoids cultivated for 72 h following CM
seeding.
VEGF ligand addition and VEGF antibody neutralization
experiments. We aimed to measure the effects of neutral-
izing endogenously secreted VEGF on Cx43 expression in
cardiac organoids, as well as to measure the Cx43 levels after
stimulating organoids with exogenously added VEGF. Ac-
cordingly, Simultaneous Preculture organoids were grown in
CM/FB medium (see Supplementary Data) supplemented
with VEGF neutralizing antibody (Anti-rat VEGF Antibody,
AF564; R&D Systems) at a concentration of 0.4 mg/mL,
corresponding to twice the neutralization dose50 (ND50).
Simultaneous Tricultures were grown in CM/FB medium
with or without VEGF ligand (VEGF-A165; R&D Systems;
Cat. No. 293-VE) at a concentration of 30 ng/mL, corre-
sponding to more than three times the Kd of VEGF-VEGFR2
binding.16 These groups were labeled as ‘‘Simultaneous
Preculture +VEGF Ab’’ and ‘‘Simultaneous Triculture +
VEGF,’’ while control groups were labeled ‘‘Simultaneous
Preculture’’ and ‘‘Simultaneous Triculture,’’ respectively. In
these experiments, the starting percentages of ECs, FBs, and
CMs were 47%, 13%, and 40%, respectively, ensuring that the
cultivation conditions were identical to our earlier work.4,14
The organoids were cultivated for either (i) 1 h, followed by
RNA extraction by TRIzol and quantitative polymerase
chain reaction (QPCR), or (ii) 24 h, followed by protein ex-
traction for Western blotting, ensuring that the appropriate
timescale for maximal transcriptional/translational changes
in Cx43 mRNA/protein was captured.
VEGFR2 small molecule inhibitor/VEGF ligand addition
studies. To test the effect of inhibiting the VEGF receptor
VEGFR2 on Cx43 mRNA and protein levels, we used a small
FIG. 1. Endogenous vascular endothelial
growth factor (VEGF) secretion. (A) Time
points for collection of culture medium and
enzyme-linked immunosorbent assay (ELI-
SA) analysis of endogenous VEGF levels
were chosen to determine the amount of
VEGF present prior to or after seeding steps
or medium changes, including the point at
which Enriched cardiomyocytes (CMs) were
seeded in the various Preculture and Tri-
culture groups. Control groups included
endothelial cells (EC) only, fibroblasts (FB)
only, and Preculture with EC only or
Preculture with FB only (Preculture ECs/
Preculture FBs). (B) Bulk VEGF secretion rate
in [ng/(mL$h)]. Graph shown in log scale. In
general, VEGF secretion rate was found to be
largest in the Preculture groups compared
with Simultaneous Triculture and peaked
maximally at 1 h after seeding CM. Within
the Preculture groups, Sequential Preculture
of ECs followed by FBs and then by CMs
(Sequential Preculture) had the highest
VEGF secretion rate compared with Si-
multaneous Preculture where ECs + FBs were
seeded together followed by CMs (Simulta-
neous Preculture) or Preculture with only
FBs or ECs (Preculture ECs/Preculture FBs).
As expected, low VEGF levels were found in
the Sequential Preculture using cells with
siRNA VEGF knockdown (Seq. Preculture +
VEGF siRNA). Note: No VEGF was detected
in organoids having only FBs or ECs (ECs
only, FBs only). n = 4/group. Horizontal lines
represent statistically significant difference
( p< 0.05) between the two groups at the ends
of the line. Color images available online at
www.liebertonline.com/tea
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molecule kinase inhibitor of VEGFR2 (Cat. No. CB676489;
Calbiochem; 19.4 nM). The inhibitor is an adenosine triphos-
phate (ATP)-competitive, reversible inhibitor with an in-
hibitory concentration50 (IC50) of 19.4 nM, the concentration
at which 50% of the VEGFR2 receptors are inhibited. The
effect of the inhibitor concentration (2.4 - 310 nM) on viability
of Enriched CMs (live/dead staining) was also studied. Se-
quential Preculture organoids as well as Enriched CM or-
ganoids were cultivated in the presence or absence of
VEGFR2 inhibitor (denoted ‘‘I,’’ 19.4 nM) and in the presence
or absence of VEGF ligand (denoted ‘‘V,’’ 30 ng/mL) in four
possible combinations: ( -V - I), (+V - I), (-V + I), and (+V
+ I). The organoids were sampled after 1 h for mRNA isola-
tion and QPCR analysis, after 24 h for protein isolation and
Western blotting analysis, or after 72 h for PFA fixation,
cryosectioning, and immunofluorescence microcopy.
siRNA knockdown of VEGF in sequential preculture.
Primary ECs, FBs, and CMs were transfected upon individ-
ual monolayer culture with a custom siRNA-designed
(Ambion/Life Technologies) targeting VEGF-A knockdown
with the following sequence: 5¢-CCAAAGAAAGAUAG
AACAAtt (21 bp)—sense; 5¢-UUGUUCUAUCUUUCUUU
GGtc (21 bp)—antisense, as described in detail in Supple-
mentary Methods. After 24 h, the cells were used to cultivate
Sequential Preculture organoids as described under ‘‘Ex-
perimental Design’’.
Assessments
VEGF-ELISA was performed according to manufacturer’s
protocols (Peprotech, Quebec; Cat. No. 900-K99). Cryosection-
ing and immunofluorescence staining for Cx43 and cell-specific
markers cardiac troponin T (cTnT) for CMs, VE-cadherin for
ECs, and vimentin for nonmyocytes (FBs+ECs) were per-
formed as in our previous work.4,13 QPCR was performed to
quantify Cx43 mRNA expression using GAPDH as a house-
keeping gene.14 Western blotting was performed using com-
mercially available reagents, antibodies for Cx43 and GAPDH,
and precast gels according to a standard protocol. Live cell
analytical flow cytometry was performed to quantify VEGFR2
expression in ECs, FBs, and CMs using a protocol previously
described.4 Electrical field stimulation was used to determine
the effect of inhibiting VEGF signaling on cardiac function
using methods we described previously.4,13,14,17 Detailed pro-
cedures are described in Supplementary Data.
Statistical data analysis. Data are presented as aver-
age – standard deviation. Statistically significant differences,
unless otherwise indicated, are denoted with horizontal bars
or asterisks. All statistical calculations were performed using
SigmaStat 3.0 (SPSS, Inc.). One-way analysis of variance
(ANOVA) in conjunction with the Holm-Sidak post hoc test
was used to compare three or more groups or two groups
versus control, while t-test was used for pairwise compari-
sons. Normality of data and equality of variance were
checked for all comparisons. Where normality failed, one-
way ANOVA on ranks was performed using a Mann-
Whitney test. Where equality of variance failed, ANOVA on
ranks in conjunction with Dunn’s test and multiple pairwise
comparisons was performed. A p-value < 0.05 was consid-
ered statistically significant for all tests.
Results
VEGF secretion rates were higher in preculture
than in simultaneous culture
Our first aim was to test whether VEGF levels were higher
in the Preculture groups compared with Simultaneous Tri-
culture group at key time points coinciding with culture
medium change or cell seeding (Fig. 1A). Endogenous VEGF
secretion rates were initially low [< 2 ng/mL/h] prior to CM
seeding (Fig. 1B), and rapidly increased 1 h after CM seeding
in all Preculture groups as compared with Simultaneous
Triculture group, where the secretion rate was below de-
tectable limits. Within the Preculture groups, Sequential
Preculture had the highest VEGF secretion rate at the time of
CM seeding [16.6 ng/mL/h; Fig. 1B] compared with
Simultaneous Preculture [8.9 ng/mL/h; Fig. 1B], or Pre-
culture with only FBs or ECs (Preculture FBs, 4.3 ng/mL/h;
Preculture ECs, 0 ng/mL/h; Fig. 1B). We could not detect
any VEGF in organoids formed through seeding of only one
cell type (FBs or ECs; Fig. 1B). By 48 h post-CM seeding,
endogenous VEGF was below detectable limits in all groups.
Expression of VEGFR2 in ECs, FBs, and CMs
Flow cytometry indicated that rat microvascular ECs dis-
played the highest percentage of VEGFR2+ cells (86%– 2%),
as expected (Fig. 2). Cardiac FBs and CMs also showed ev-
idence of VEGFR2 + cells, but the percentages were lower
(FBs: 44% – 1%, CMs: 49%– 2%) (Fig. 2).
Cx43 mRNA is maximally upregulated
within 1 h of VEGF stimulation
To determine the optimal time point for mRNA isolation
after VEGF stimulation, we performed a time course exper-
iment on CM monolayers grown in medium containing a
nonlimiting concentration of VEGF (800 ng/mL) and mea-
sured Cx43 mRNA levels at various time points between 0
and 12 h (see Supplementary Fig. S1; Supplementary Data
are available online at www.liebertonline.com/tea). Cx43
mRNA was shown to be maximally upregulated within 1 h
of stimulation with VEGF, after which basal mRNA levels
were again reached between 4 and 12 h after stimulation
(Supplementary Fig. S1). All subsequent QPCR evaluations
were therefore performed using mRNA harvested at the 1-h
time point.
Neutralizing secreted VEGF in precultured organoids
lowers Cx43 mRNA and protein expression
To test the effect of neutralizing endogenously secreted
VEGF ligand, we added a VEGF neutralizing antibody
(0.4 mg/mL) to Simultaneous Preculture organoids. After 1 h
of treatment, Cx43 mRNA levels decreased by nearly three-
fold in the Simultaneous Preculture group compared with
the Simultaneous Preculture control (Fig. 3A, white bars).
Western blotting indicated that Cx43 protein levels in
Simultaneous Preculture were higher than for Enriched
CMs (Fig. 3B, white bars) while in Simultaneous Preculture
with the VEGF Ab, the protein levels dropped by *1.5-fold
to a value lower than Enriched CMs (white bars/dashed line,
Fig. 3B).
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Addition of exogenous VEGF ligand to Simultaneous
Triculture organoids increases Cx43 mRNA
and protein expression
We also added VEGF ligand (30 ng/mL) to Simultaneous
Triculture to test the effect of VEGF supplementation in
cardiac organoids with low levels of endogenous VEGF. The
Simultaneous Triculture+VEGF Ligand group had threefold
higher Cx43 mRNA levels than the Simultaneous Triculture
control (Fig. 3A, black bars). In fact, Cx43 transcript levels in
Simultaneous Triculture +VEGF Ligand were comparable to
those of Simultaneous Preculture alone as well as those
found in Enriched CMs (dashed line, Fig. 3A). Western
blotting showed that in Simultaneous Triculture +VEGF Li-
gand organoids, the Cx43 protein levels also increased by
more than twofold compared with the VEGF-free Simulta-
neous Triculture controls (Fig. 3B, black bars).
The VEGFR2 inhibitor is not cytotoxic
at its inhibitory concentration
We evaluated the cytotoxicity of a small molecule,
competitive inhibitor of VEGFR2 inhibitor (IC50 = 19.4 nM).
Cell viability was quantified over inhibitor concentrations
FIG. 2. VEGFR2 expression. Analytical flow cytometry for VEGFR2 expression was performed on live rat microvascular
endothelial cells [RMVECs, (A)], neonatal cardiac fibroblasts [CFBs, (B)] passaged once, and Enriched CMs [enriched by two
preplating steps on adherent tissue culture flasks, (C)]. Scatter plots (top row) show the size distribution and granularity of the
various cell types as well as gating out of debris and smaller red blood cells. Histograms show unstained controls (middle row,
black outline) and controls stained with only secondary antibody (fluorescein isothiocyanate Goat Anti-Rabbit, 1:25). Histo-
grams of cells stained with primary antibody (Rabbit Anti-Flk-1, 1:25) and secondary antibody are shown in the bottom row.
Color images available online at www.liebertonline.com/tea
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ranging from 2.4 nM to 310 nM, revealing no cytotoxicity
in CM monolayers grown at concentrations up to 77 nM,
above which we saw a greater number of dead cells (Sup-
plementary Fig. S2, red nuclei). We therefore used a con-
centration of 19.4 nM in all of our VEGFR2 inhibition studies
to prevent cytotoxicity and nonspecificity (see the Discussion
section).
Inhibition of the VEGFR2 receptor downregulates
Cx43 mRNA and protein expression
To test the effect of inhibiting the VEGFR2 receptor on
Cx43 expression, we cultivated organoids based on Se-
quential Preculture, using Enriched CMs as a baseline, in the
presence or absence of the VEGFR2 inhibitor (I) as well as in
FIG. 3. Effects of VEGF neutralizing antibody and VEGF addition on Connexin 43 mRNA and protein levels in cardiac
organoids. Simultaneous Preculture organoids were cultivated by simultaneously co-culturing the nonmyocytes (FBs and
ECs) for 2 days prior to seeding of Enriched CMs in the absence (Simultaneous Preculture, white bars) or presence of Anti-
VEGF neutralizing IgG at 0.4 mg/mL (Simultaneous Preculture +VEGF Ab, white bars). Simultaneous Triculture organoids,
where all three cell types were seeded at the same time, were grown in medium alone (Simultaneous Triculture, black bars) or
medium containing VEGF Ligand at 30 ng/mL (Simultaneous Triculture +VEGF Ligand, black bars). Enriched CM organoids
served as a baseline (dashed lines). (A) A decrease in Cx43 mRNA levels was observed in the Simultaneous Preculture +
VEGF Ab by QPCR, n = 3/group. (B, C) Western blotting for Cx43 (43 kDa) and GAPDH (36 kDa), n = 4/group. (B) Band
densitometry analysis showed that Cx43 protein levels were downregulated relative to the control and baseline conditions in
Simultaneous Preculture supplemented with Anti-VEGF neutralizing IgG, while for Simultaneous Triculture, Cx43 protein
levels were increased relative to the control and baseline conditions when supplemented with VEGF ligand. (C) Re-
presentative image showing band intensities for GAPDH and Cx43 protein. Horizontal lines represent statistically significant
difference ( p< 0.05) between the two groups at the ends of the line. * indicates significant difference compared with the
dashed line, which represents the value for Enriched CMs.
1776 IYER ET AL.
the presence or absence of VEGF ligand (V). Addition of
VEGF alone to Enriched CMs (+V - I, third bar, Fig. 4A)
resulted in mRNA levels comparable to the control (Enriched
CMs -V - I) but significantly higher than both of the
inhibited groups (-V + I and +V + I, Fig. 4A). Notably,
Enriched CM organoids grown in the presence of both VEGF
ligand and the VEGFR2 inhibitor (+V + I, Fig. 4A) showed a
1.4-fold drop in Cx43 mRNA levels that was comparable to
the inhibited case (-V + I, Fig. 4A). In the Sequential Pre-
culture group, a similar trend was seen, with a 1.5-fold
increase in Cx43 mRNA in the presence of VEGF alone (+V
- I, Fig. 4B) that was significantly higher than both the in-
hibited cases (-V + I and +V + I, Fig. 4B).
Enriched CM organoids grown for 24 h in the presence of
VEGFR2 inhibitor alone (-V + I, Fig. 4C) also expressed 1.3-
fold less Cx43 protein relative to the control, while the
presence of VEGF ligand alone (+V - I, Fig. 4C) resulted in
Cx43 protein levels that were comparable to the control but
significantly higher than both the inhibited cases (-V + I and
+V + I, Fig. 4C). Addition of both VEGF ligand and the
inhibitor in combination (+V + I, Fig. 4C) had a similar effect
to adding the inhibitor alone, causing a statistically signifi-
cant twofold downregulation in Cx43 protein. A similar
trend in Cx43 protein levels was seen in Sequential Pre-
culture (Fig. 4D, white bars), but the changes were more
dramatic, with a 4.1-fold decrease in Cx43 protein levels in
the presence of inhibitor alone (-V + I, Fig. 4D) and a 2.5-
fold decrease in Cx43 protein in the presence of both the
inhibitor and VEGF ligand (+V + I, Fig. 4D). Interestingly,
addition of VEGF ligand in the absence of VEGFR2 inhibitor
to Sequential Preculture organoids did not increase Cx43
protein levels above those of the control (+V - I, Fig. 4D),
FIG. 4. Effects of VEGFR2 inhibition on Cx43mRNA and protein levels in cardiac organoids. (A, B) VEGF Ligand (V, 30 ng/
mL) or VEGFR2 inhibitor (I, 19.4 nM) was added to organoids based on either Enriched CMs or Sequential Preculture. In the
presence of the inhibitor alone (-V + I), Cx43 mRNA levels were lowered in Enriched CMs (A, black bars) and Sequential
Preculture (B, white bars). Addition of exogenous VEGF ligand alone (+V - I) at 30 ng/mL improved Cx43 mRNA expres-
sion in both Enriched CMs and Sequential Preculture but these levels were not significant relative to the control (-V - I).
Importantly, addition of VEGF ligand to inhibited organoids (+V + I) did not improve Cx43 mRNA levels, which were
comparable to mRNA levels for organoids grown in the inhibitor alone (-V + I). n= 3/group. Dashed line in (B) represents the
Cx43mRNA expression for Sequential Preculture group using cells with siRNA VEGF knockdown. (C, D)Western blotting for
Cx43 protein normalized to a GAPDH loading control. n= 3/group. Horizontal lines represent statistically significant difference
( p< 0.05) between the two groups at the ends of the line. (E) Representative blots showing the amount of protein in each lane.
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suggesting that endogenous VEGF levels were already some-
how optimized in this condition. This was in contrast to the
Simultaneous Triculture case, where addition of exogenous
VEGF increased both Cx43 mRNA and protein levels (Si-
multaneous Triculture+VEGF Ligand; Fig. 3A, B, black bars).
We measured VEGF secretion rate in the Sequential Pre-
culture siRNA group and found it to be significantly lower
than Sequential Preculture without siRNA knockdown (Fig.
1B).We also found that the siRNASequential Preculture group
had significantly lower level of Cx43 expression than other
groups (Fig. 4B), thus supporting the link between autocrine
VEGF secretion and upregulation of Cx43 in preculture.
Cx43 is found primarily in CMs, and not in FBs or ECs
Organoids based on Enriched CMs alone stained abun-
dantly for both cTnT (Fig. 5, green intracellular staining) and
Cx43 (Fig. 5, red punctate staining) and the Cx43 was asso-
ciated with cTnT + cells (Fig. 5A, left). However, the cTnT +
cells were rounded in the Enriched CM groups and did not
exhibit evidence of striations, indicative of an immature
phenotype. Cx43 was found in the areas not positive for VE-
cad or Vim; that is, the CMs (Fig. 5A, center and right).
Similar results were obtained when performing double
immunofluorescence staining on Sequential Preculture
organoids (Fig. 5B), where Cx43 was found primarily in the
vicinity of cTnT + cells (Fig. 5B, left). Moreover, cells in
Sequential Preculture organoids were much more elongated
and cTnT + cells showed evidence of muscle striations,
consistent with a differentiated phenotype.
Cx43 is diminished in the presence
of VEGFR2 inhibitor
Consistent with our Western blotting data, we identified
higher levels of Cx43 by immunostaining in the control (-V
- I, Fig. 6A) and VEGF ligand only–supplemented Enriched
CM organoids (+V - I, Fig. 6A) compared with the groups
with the inhibitor present (-V + I and +V + I). Similar effects
of the inhibitor on Cx43 immunostaining were observed in
the Sequential Preculture groups (Fig. 6B). In addition, cTnT
staining was more disorganized in both Sequential Pre-
culture groups cultivated with the inhibitor, while the
control and VEGF-ligand-supplemented groups showed ev-
idence of cell elongation and muscle striations (Fig. 6B, top
and bottom).
Addition of VEGFR2 inhibitor during cultivation
negatively affects contractile properties
of cardiac organoids
Functional testing was performed to measure the effect
of VEGF stimulation/VEGFR2 inhibition on the excitation
FIG. 5. Localization of Cx43. Frozen sections of Enriched CMs and Sequential Preculture organoids grown for 72h were
fluorescently labeled with antibodies for Cx43 (red) as well as the cell-specific markers cardiac troponin T (cTnT, left, green, CMs),
VE-cadherin (VE-cad, center, green, ECs), and Vimentin (Vim, right, green, ECs+FBs). 4¢,6-Diamidino-2-phenylindole was used as
a nuclear counter stain (blue). (A, left) cTnT was found abundantly in Enriched CM organoids and was always associated with
Cx43 (red). However, cTnT+ cells were much more rounded in Enriched CM organoids compared with the Sequential Preculture
organoids, in which cell elongation was marked and striations were visible (B, left). (A, center) VE-cadherin staining (green) was
sparse and primarily not associated with Cx43 (red) in either Enriched CMs or Sequential Preculture (B, center). (A, right)
Vimentin staining (green) was not found to be co-localized with Cx43 (red) in either Enriched CM organoids or Sequential
Preculture (B, right). Scale bars are 25mm in all panels and insets. Color images available online at www.liebertonline.com/tea
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threshold (ET) and maximum capture rate (MCR) of en-
gineered organoids (see Supplementary Data). Low values of
ET and high values of MCR are desirable in this assessment
as they point to improved coupling between CMs. Enriched
CM-based organoids supplemented with VEGFR2 inhibitor
had compromised functional properties, displaying an ele-
vated ET (-V + I and +V + I, Fig. 7A, top left) compared
with the inhibitor-free controls. Addition of VEGF ligand
alone did not appear to lower the ET in Enriched CM or-
ganoids relative to the control (+V - I vs. -V - I, Fig. 7A).
The MCR was significantly lower in the presence of the in-
hibitor alone ( -V + I, Fig. 7A, top right) compared with the
VEGF-ligand-supplemented groups (both +V - I and +V
+ I, Fig. 7A, top right), but not appreciably different relative
to the control ( -V - I). For Sequential Preculture, the addi-
tion of VEGF alone (+V - I, Fig. 7B) showed a statistically
significant drop in ET relative to the inhibited groups, both
of which had a high ET and a low MCR ( -V + I and +V + I,
Fig. 7B, bottom). In the group containing both the inhibitor
as well as the VEGF ligand ( +V + I, Fig. 7B, right most bar),
FIG. 6. Effect of the
VEGFR2 inhibitor on Cx43 in
cardiac organoids. Enriched
CMs or Sequential Preculture
organoids grown in the pres-
ence or absence of VEGF Li-
gand (V) or VEGFR2
Inhibitor (I) for 72 h were
double immunostained for
Cx43 (red) and cTnT (green).
(A) Enriched CM organoids
grown without either inhibi-
tor or VEGF ligand ( -V - I)
as well as organoids grown in
the presence of VEGF ligand
alone (+V - I) expressed
similar levels of Cx43 protein,
but the presence of VEGFR2
inhibitor ( -V + I) visibly di-
minished the Cx43 protein
expression. Exogenous VEGF
ligand added to the inhibited
organoids (+V + I) did not
improve Cx43 levels. In all
inhibited groups, cTnT was
disorganized and dimin-
ished. (B) Sequential Pre-
culture organoids grown in
the absence of VEGF ligand/
VEGFR2 inhibitor (-V - I) or
in the presence of VEGF li-
gand alone (+V - I) showed
robust Cx43 expression and
evidence of cell elongation
and muscle striations in
cTnT + cells. This was in
stark contrast to organoids
grown in VEGFR2 inhibitor
( -V + I and +V + I) that
displayed diminished Cx43, a
rounded morphology, disor-
ganized cTnT expression, and
absence of striations. Scale
bars are 25mm in all panels
and insets. Color images
available online at www
.liebertonline.com/tea
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the MCR was significantly lower than both the control (-V
- I, Fig. 7B, bottom right) and the group containing VEGF
ligand alone (+V - I, Fig. 7B, bottom right).
Another important measure of contractile function in the
organoids was the ratio of samples that could be induced to
beat synchronously divided by the total number of samples
we tested (Fig. 7). While all Enriched CM organoids had
success rates of 1.0, this was not the case with Sequential
Preculture, where the inhibited groups (-V + I and +V + I,
Fig. 7) had success rates of 0.5 and 0.6, indicating poorer
electrical coupling of the cells.
Discussion
The main goal of this study was to elucidate the mecha-
nisms responsible for improved functional assembly of car-
diac organoids by preculture with nonmyocytes. In our
previous work4 we determined that although conditioned
media from EC/FB produced increase in Cx43 im-
munostaining in cardiac organoids, the most robust im-
provement in functional properties was observed in
Preculture, thus motivating detailed studies of Preculture
groups here and omitting the conditioned media group. We
found that VEGF was rapidly released immediately after CM
seeding in the Simultaneous Preculture and Sequential Pre-
culture groups, in contrast to Simultaneous Triculture where
no VEGF could be detected, and that blocking endogenous
VEGF or VEGFR2 resulted in transcriptional and transla-
tional downregulation of Cx43. Conversely, supplementation
with VEGF ligand resulted in transcriptional and transla-
tional upregulation of Cx43 and improved cardiac function.
We also found that all three cell types used in our studies
A
B
FIG. 7. Effect of the VEGFR2 inhibitor on electromechanical properties of cardiac organoids. Organoids based on Enriched
CMs and Sequential Preculture were grown for 72 h in the presence or absence of VEGF ligand (V) or a VEGFR2 inhibitor (I).
Excitation threshold (ET, V/cm, left) and maximum capture rate (MCR, Hz, right) were measured to assess electrical
excitability in the presence or absence of inhibitor or VEGF. In general, all inhibited Enriched CM organoids exhibited poorer
contractile function with higher ETs (A, left) and lower MCR (A, right), as did all inhibited Sequential Preculture organoids
(B, left/right). Addition of VEGF ligand alone (+V - I) maintained ET and MCR at values comparable with or better than the
control (-V - I), but was ineffective in improving the ET/MCR in the presence of the inhibitor (+V + I). n= 3–5/group.
Success rate of beating organoid formation, defined as the number of samples that could be induced to beat divided by the
total number of samples tested during functional testing, was reported under the ET graph for each group. In the case of
Enriched CM organoids, the success rate was always 1, indicating all samples could be induced to contract. However, for
Sequential Preculture, the success rate was only 1 in the control (-V - I) and VEGF-ligand-supplemented group (+V - I). The
inhibited groups had success rates lower than 1, suggesting that fewer samples were able to contract in the presence of the
inhibitor, even in the presence of VEGF ligand. Horizontal lines represent statistically significant difference ( p< 0.05) between
the two groups at the ends of the line.
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(ECs, FBs, and CMs) expressed VEGFR2 but Cx43 expression
was localized to CM alone. These findings suggest a putative
mechanism whereby VEGF, secreted by nonmyocytes during
the Preculture period, may be stored and released to bind
with VEGFR2 on CMs, which, in turn, respond by synthe-
sizing Cx43 mRNAs and proteins to improve cell–cell
communication and organoid function. This proposed
mechanism is consistent with our previous observations that
showed that conditioned medium from Simultaneous Pre-
culture organoids also improved the morphology, cell den-
sity, and viability of organoids based on Enriched CMs,4
which suggested to us early on that a soluble factor might be
regulating these effects. We also previously observed EC
clustering, lack of contractile function, and lack of Cx43 ex-
pression in Simultaneous Triculture,4 consistent with lower
VEGF levels,11 which motivated us to evaluate endogenous
VEGF secretion under different cell culture conditions.
We did not investigate the effect of Sequential Preculture
in order of FBs, ECs, and CMs, since we attempted to capture
a developmentally relevant situation whereby endothelial
progenitors appear before the appearance of other cardiac
cell types.18
Since the Kd of VEGF-VEGFR2 binding is *10 ng/mL
[16], and the average VEGF secretion rates detected in the
Preculture groups were of the same order of magnitude
[between 4.3 ng/(mL$h - 1) and 16.6 ng/(mL$h- 1)], the suc-
cess of preculture may be in its ability to maintain VEGF at
concentrations at or above the threshold required for sig-
naling with VEGFR2. Addition of exogenous soluble VEGF
to the Sequential Preculture organoids did not result in an
increase in Cx43 expression. It is possible that this is because
VEGF levels are already high in this condition, and thus,
VEGFR2 receptors may be saturated and additional exoge-
nous VEGF may not improve Cx43 levels beyond baseline
levels for this condition.
All three cell types seeded into the organoids (ECs, FBs,
and CMs) expressed VEGFR2, indicating that they could
respond to changes in the VEGF concentration. We observed
a bimodal distribution when performing flow cytometry
for VEGFR2 on neonatal rat CMs, with 49% of the Enriched
CMs displaying a VEGFR2+ phenotype. However, this
VEGFR2 + subpopulation may have contained both myo-
cytes and nonmyocytes, since the purity of Enriched CMs
after two preplates is only *81%.4 Thus, even if we assume
the remaining 19% of nonmyocytes to have contributed to
this shift, then only 49%–19% =*30% of the CMs were
VEGFR2 + . Nonetheless, this still implies the existence of a
definite VEGFR2+ CM subpopulation capable of responding
to changes in VEGF, including potentially synthesizing
connexin mRNAs and proteins.
Regulation of Cx43 at the transcriptional (mRNA) and
translational (protein) levels was shown through VEGF
blocking and supplementation experiments. The choice of
the 1-h time point for measurement of Cx43 mRNA was
based on a half-life of typical mRNA around 30min–1 h.
Others have shown that Cx43 mRNA peaks early on after
mechanical stimulation of CMs (i.e., minutes to a couple of
hours).19,20 Indeed, our time course experiments confirmed
this time frame for maximal Cx43 mRNA upregulation after
VEGF stimulation (Supplementary Fig. S1). For Western
blotting studies, however, total protein was isolated from the
organoids at 24 h posttreatment with VEGF ligand or its in-
hibitors. This was based on published reports that stated that
the half-life of Cx43 protein is short (1–2 h); however, it may
continue to be synthesized after stimulation for up to 24 h
before reaching steady-state levels.19–22
We chose a concentration of the neutralizing antibody
(0.4 mg/mL) that was twice the ND50 required to neutralize
a half of the VEGF ligand at a concentration of 30 ng/mL.
We reasoned that this concentration would be sufficient to
ensure that the majority of endogenously secreted VEGF
ligands were not available for signaling, based on our
ELISA data, where the maximum endogenous secretion rate
we detected was 16.6 ng/(mL$h- 1). In Simultaneous Tri-
culture, we also observed significant increases in Cx43 ex-
pression at both the transcriptional and translational levels
when supplementing the organoids with soluble VEGF-A165
at 30 ng/mL. We chose this concentration since it was three
times higher than the Kd of VEGF-VEGFR2 binding,
16
which ensured that we were not below the threshold for
signaling.
To assess the contribution of VEGF-VEGFR2 binding to
Cx43 regulation, we cultivated organoids in the presence of a
small molecule, ATP-competitive VEGFR2 inhibitor. We did
not use concentrations above the IC50 of 19.4 nM in our ex-
periments, since the inhibitor is not specific to VEGFR2
alone, and has been reported to inhibit other receptor tyro-
sine kinases at higher concentrations (PDGFRb IC50 = 34 nM,
VEGFR3 IC50 = 190 nM, etc.). Still, this ensured that at least
50% of the VEGFR2 receptors would not be able to partici-
pate in VEGF signaling. Dose–response experiments also
confirmed that no cytotoxicity was observed at 19.4 nM
(Supplementary Fig. S2), which further motivated us to use
this concentration. Interestingly, the inhibitor was effective in
downregulating Cx43 mRNA and protein levels even in the
presence of a high concentration of exogenously added
VEGF ligand of 30 ng/mL (all +V + I groups). This was
likely due to the fact that the inhibitor, although reversible,
was an ATP-competitive inhibitor, meaning that the ATP
binding pocket would still have been inaccessible in at least
50% of the receptors at a concentration of 19.4 nM, even in
the presence of an excess of exogenous VEGF ligand.
A higher ET and a lower MCR (Fig. 7) in all groups con-
taining the inhibitor were consistent with lower levels of
Cx43 mRNA/protein observed in these groups (Fig. 4). The
worsened contractile properties may be indicative of di-
minished capacity for functional coupling of CMs through
gap junctions. It is unlikely that the worsened contractile
properties were due to cell death since our inhibitor dose–
response studies ruled out this possibility (Supplementary
Fig. S2).
VEGF-VEGFR2 signaling is known to influence a myriad
of cellular responses by regulating several downstream ef-
fectors. One of these downstream effectors is mitogen-acti-
vated protein kinase (MAPK), known for its regulation of
cell cycle genes, such as c-myc.23,24 MAPK signaling has also
been shown to affect Cx43 expression.5,25 It is possible,
therefore, that VEGF-VEGFR2 binding regulates Cx43 ex-
pression by way of the MAPK pathway and its downstream
targets. Another possibility, as hypothesized by Pimentel
et al., is that VEGF may inactivate the degradatory pathways
for Cx43 mRNAs and proteins.10 The complexity and large
number of possible pathways underscore the need for fur-
ther work in order to fully elucidate the precise downstream
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targets of VEGF-VEGFR2 binding that may regulate Cx43
expression.
Our data strongly point at the possible causal relationship
between VEGF-VEGFR2 signaling and Cx43 mRNA/protein
regulation. We also propose that the VEGF may be secreted
by nonmyocytes and/or stored in the ECM for later release.
This signaling mechanism represents a novel finding with
potentially useful applications for tissue engineering. For
example, engineered cardiac tissues based on multiple cell
populations may benefit from the addition of VEGF ligand to
culture medium to aid in promoting cardiac differentiation
and development and to ensure gap junctional expression is
robustly maintained. Alternatively, biomaterials can be de-
signed to provide sustained or bolus release of VEGF, coin-
ciding with crucial cell seeding time points. Most
importantly, the use of Preculture as a cell seeding meth-
odology itself presents a method of ensuring that endoge-
nously secreted VEGF is maintained at physiologically
relevant levels capable of improving gap junction/cell–cell
communication and, in turn, proper cardiac contractile
function.
While our results indicated that VEGF is secreted early on
after CM seeding, there is very little endogenous VEGF se-
cretion later on, suggesting that other signaling mediators
and growth factors may be important in maintaining Cx43
expression throughout the 7-day cultivation period. While
we focused primarily on VEGF for our studies, it should be
noted that there are also other soluble factors worthy of in-
vestigation besides VEGF, such as Angiotensin II, Angio-
poietin 1, Endothelin-1, neuroreglin, nitric oxide, and
transforming growth factor-b,26 which could have addi-
tional, equally important roles and may lead to potentially
undiscovered mechanisms regulating cardiac function dur-
ing the tissue engineering process. Additionally, factors that
are important in early cardiac development, such as fibro-
blast growth factor, bone morphogenetic protein, and Wnt
may also guide the development of functional cardiac tissues
in vitro and should be investigated in further studies. In fu-
ture studies, it is also necessary to scale up the cell compo-
sitions to the millimeter-size cardiac tissue relevant for
implantation and demonstrate the success of precultured
patches in improving cardiac function in vivo.
Conclusions
Mechanistic studies were carried out to elucidate the role
of VEGF-VEGFR2 signaling on Cx43 expression in en-
gineered cardiac tissues based on Sequential Preculture, Si-
multaneous Preculture, Simultaneous Triculture, and
Enriched CMs. These studies revealed that VEGF secreted by
nonmyocytes modulated the Cx43 levels both at the tran-
scriptional and translational levels. VEGF secretion peaked
immediately upon seeding of CMs and was highest in the
Sequential Preculture group. Blockage of the endogenous
pool of secreted VEGF in Simultaneous Preculture through a
neutralizing antibody resulted in significant downregulation
of Cx43 mRNA and protein (shown through QPCR and
Western blotting data). Meanwhile addition of VEGF ligand
to Simultaneous Triculture resulted in upregulation of Cx43
mRNA and protein to levels comparable with Simultaneous
Preculture. We found that all three cell types (ECs, FBs, and
CMs) expressed the VEGFR2 receptor by analytical flow
cytometry, but the majority of Cx43 protein was expressed
by CMs as shown by double staining of Cx43 with cell-
specific markers. Inhibition of the VEGFR2 receptor in
Sequential Preculture and Enriched CMs using a small
molecule inhibitor also resulted in downregulation of Cx43
mRNA transcripts and protein as shown through QPCR,
Western blotting, and double immunofluorescence staining.
Contractile function was also compromised in VEGFR2-
inhibited organoids, which had poor functional properties
(overall higher ET and lower success rate). The data pre-
sented here may provide new insights into VEGF-VEGFR2-
Cx43 signaling dynamics during the tissue engineering
process. Our findings may aid in the design and im-
plementation of novel therapies for cardiac tissue engineer-
ing and regeneration.
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